BRI-12349
BRI-12349 (Compound 50) is a dual antagonist of CysLT1R/CysLT2R with Ki values of 1.03 and 6.46 μM. BRI-12349 can inhibit the generation of IP1 induced by LTD4 (the main ligand of CysLTs) . BRI-12349 can be used for the research of immunology and inflammation, such as asthma[1].
Product Specifications
CAS Number
[920707-33-1]
UNSPSC
12352005
Target
Leukotriene Receptor
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
O=C(C1=C(NC(CSC2=NN=C(C3=CNC4=C3C=CC=C4)O2)=O)SC=C1)N
Molecular Formula
C17H13N5O3S2
Molecular Weight
399.45
References & Citations
[1]Арман Арманович САДЫБЕКОВ, et al. Cysteinyl leukotriene receptor ligands directed toward the treatment of inflammatory and oncological diseases. WO2022255900A1. 2023-12-02
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
LTC4/CysLT2; LTD4/CysLT1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1405317-01 0.02 mg (E-Coli)
Recombinant Human Katanin p80 WD40-containing subunit B1 (KATNB1)
Ask
View Details 
MBS1405317-02 0.02 mg (Yeast)
Recombinant Human Katanin p80 WD40-containing subunit B1 (KATNB1)
Ask
View Details 
MBS1405317-03 0.1 mg (E-Coli)
Recombinant Human Katanin p80 WD40-containing subunit B1 (KATNB1)
Ask
View Details MBS1405317-04 0.1 mg (Yeast)
Recombinant Human Katanin p80 WD40-containing subunit B1 (KATNB1)
Ask
View Details MBS1405317-05 0.02 mg (Baculovirus)
Recombinant Human Katanin p80 WD40-containing subunit B1 (KATNB1)
Ask
View Details MBS1405317-06 0.02 mg (Mammalian-Cell)
Recombinant Human Katanin p80 WD40-containing subunit B1 (KATNB1)
Ask
View Details